EXAGEN INC.
Qualité des données : 100%
XGN
Nasdaq
Services
Health Services
3,03 €
▼
0,06 €
(-1,94%)
Cap. Boursière: 74,32 M
Prix
3,09 €
Cap. Boursière
74,32 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue grew 8,35% annually over 5 years — modest growth
Negative free cash flow of -14,27 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 11,30%
Capital efficient — spends only 0,96% of revenue on capex
Croissance
Revenue Growth (5Y)
8,35%
Au-dessus de la moyenne du secteur (3,99%)
Revenue (1Y)19,65%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-101,86%
En dessous de la moyenne du secteur (-15,85%)
ROIC-22,59%
Net Margin-29,97%
Op. Margin-21,13%
Sécurité
Debt / Equity
1,26
Au-dessus de la moyenne du secteur (0,39)
Current Ratio4,08
Interest Coverage-3,26
Valorisation
PE (TTM)
-3,73
En dessous de la moyenne du secteur (-1,21)
P/B Ratio4,10
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Services (506 pairs)
Comparaison Sectorielle
vs médiane du secteur Services (506 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -3,7 | -1,2 |
| P/B | 4,1 | 1,4 |
| ROE % | -101,9 | -15,8 |
| Net Margin % | -30,0 | -18,3 |
| Rev Growth 5Y % | 8,4 | 4,0 |
| D/E | 1,3 | 0,4 |
Objectif de Cours des Analystes
6 analystes
Buy
Actuel
3,03 €
Objectif
9,50 €
8,00 €
10,00 €
10,00 €
Prévisions
P/E Prévisionnel
-9,77
BPA Prévisionnel
-0,31 €
CA Est.
79,74 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-0,31 €
-0,49 € – -0,13 €
|
79,74 M | 2 |
| FY2026 |
-0,80 €
-0,80 € – -0,80 €
|
71,07 M | 1 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,20 €
-0,20 € – -0,20 €
|
17,88 M | 1 |
| 2026 Q1 |
-0,25 €
-0,25 € – -0,25 €
|
16,32 M | 1 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,19 € | -0,27 € | -37,7% |
| Q32025 | -0,16 € | -0,31 € | -96,8% |
| Q22025 | -0,15 € | -0,18 € | -18,8% |
| Q12025 | -0,21 € | -0,20 € | +3,2% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 19,65% | Revenue Growth (3Y) | 12,56% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 8,35% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 66,58 M | Net Income (TTM) | -19,95 M |
| ROE | -101,86% | ROA | -32,82% |
| Gross Margin | 58,28% | Operating Margin | -21,13% |
| Net Margin | -29,97% | Free Cash Flow (TTM) | -14,27 M |
| ROIC | -22,59% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,26 | Current Ratio | 4,08 |
| Interest Coverage | -3,26 | Asset Turnover | 1,10 |
| Working Capital | 39,70 M | Tangible Book Value | 18,14 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3,73 | Forward P/E | N/A |
| P/B Ratio | 4,10 | P/S Ratio | 1,12 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -19,19% | ||
| Market Cap | 74,32 M | Enterprise Value | 61,61 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,93 | Revenue / Share | 2,77 |
| FCF / Share | -0,59 | OCF / Share | -0,57 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,96% | FCF Conversion | 71,51% |
| SBC-Adj. FCF | -15,94 M | Growth Momentum | 11,30 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 66,58 M | 55,64 M | 52,55 M | 45,56 M | 48,30 M |
| Net Income | -19,95 M | -15,12 M | -23,69 M | -47,39 M | -26,85 M |
| EPS (Diluted) | -0,93 | -0,83 | -1,34 | -2,77 | -1,68 |
| Gross Profit | 38,80 M | 33,11 M | — | — | — |
| Operating Income | -14,07 M | -13,64 M | -22,84 M | -46,05 M | -24,07 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 6,25 M | 5,38 M | 4,87 M | 9,88 M | 7,24 M |
| SG&A Expenses | 46,62 M | 41,37 M | 47,43 M | 52,02 M | 44,54 M |
| D&A | 2,10 M | 1,70 M | 2,20 M | 1,60 M | 900 000,0 |
| Interest Expense | 4,32 M | 2,23 M | 2,34 M | 2,45 M | 2,63 M |
| Income Tax | 51 000,0 | 12 000,0 | 33 000,0 | -282 000,0 | 175 000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 58,02 M | 44,69 M | 56,94 M | 86,22 M | 123,45 M |
| Total Liabilities | 40,57 M | 35,15 M | 34,25 M | 43,76 M | 38,51 M |
| Shareholders' Equity | 17,45 M | 9,54 M | 22,69 M | 42,46 M | 84,94 M |
| Total Debt | 22,91 M | 20,25 M | 19,50 M | 28,97 M | 27,48 M |
| Cash & Equivalents | 32,22 M | 22,04 M | 36,49 M | 62,39 M | 99,44 M |
| Current Assets | 48,89 M | 36,46 M | 47,84 M | 72,61 M | 112,73 M |
| Current Liabilities | 14,16 M | 13,51 M | 11,90 M | 9,62 M | 9,32 M |
{"event":"ticker_viewed","properties":{"ticker":"XGN","listing_kind":"stock","pathname":"/stocks/xgn","exchange":"Nasdaq","country":"US"}}